Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | ACHE | P22303 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.37 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30367230 | 1.00 | TSHR (0.50) | TSHRACHEALDH1A1CA1CA2 | |
| Hydrochloric Acid SCHEMBL5908722 | 0.97 | TSHR (0.47) | TSHRACHEALDH1A1CA1CA2 | |
| Hydrochloric Acid SCHEMBL30217238 | 0.97 | TSHR (0.47) | TSHRACHEALDH1A1CA1CA2 | |
| Hydrochloric Acid SCHEMBL105623 | 0.97 | TSHR (0.47) | TSHRACHEALDH1A1CA1CA2 | |
| SCHEMBL4480 | 0.97 | TSHR (0.53) | TSHRACHEALDH1A1CA1CA2 | |
| SCHEMBL3127305 | 0.97 | TSHR (0.53) | TSHRACHEALDH1A1CA1CA2 | |
| SCHEMBL29357701 | 0.97 | TSHR (0.53) | TSHRACHEALDH1A1CA1CA2 | |
| Hydrochloric Acid SCHEMBL2857411 | 0.94 | TSHR (0.50) | TSHRACHEALDH1A1CA1CA2 | |
| Bromide SCHEMBL3688252 | 0.94 | TSHR (0.50) | TSHRACHEALDH1A1CA1CA2 | |
| SCHEMBL2502467 | 0.94 | TSHR (0.50) | TSHRACHEALDH1A1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210171504-A1 | Purified cenicriviroc and purified intermediates for making cenicriviroc | TOBIRA THERAPEUTICS INC (US) | 2021-06-10 | — | — | US | disclosed |
| US-20200216476-A1 | PROCESS OF MAKING CENICRIVIROC AND RELATED ANALOGS | TOBIRA THERAPEUTICS INC (US) | 2020-07-09 | — | — | US | disclosed |
| US-20200095229-A1 | Purified cenicriviroc and purified intermediates for making cenicriviroc | TOBIRA THERAPEUTICS INC (US) | 2020-03-26 | — | — | US | disclosed |
| US-10407411-B2 | Purified cenicriviroc and purified intermediates for making cenicriviroc | TOBIRA THERAPEUTICS, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-20180327428-A1 | PROCESS OF MAKING CENICRIVIROC AND RELATED ANALOGS | TOBIRA THERAPEUTICS INC (US) | 2018-11-15 | — | — | US | disclosed |
| US-20170362207-A1 | PURIFIED CENICRIVIROC AND PURIFIED INTERMEDIATES FOR MAKING CENICRIVIROC | TOBIRA THERAPEUTICS INC (US) | 2017-12-21 | — | — | US | disclosed |
| EP-3237424-A1 | PROCESS OF MAKING CENICRIVIROC AND RELATED ANALOGS | Tobira Therapeutics, Inc. (US) | 2017-11-01 | — | — | EP | disclosed |
| WO-2016105527-A1 | PROCESS OF MAKING CENICRIVIROC AND RELATED ANALOGS | TOBIRA THERAPEUTICS, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
| US-8242235-B2 | Purification process of electroluminescent material, electroluminescent material and electroluminescent device | HITACHI CHEMICAL CO., LTD. (JP) | 2012-08-14 | — | — | US | disclosed |
| US-7507351-B2 | Method for purifying electroluminescent material, electroluminescent material and electroluminescent device | HITACHI CHEMICAL CO., LTD. (JP) | 2009-03-24 | — | — | US | disclosed |
| US-20070159069-A1 | Purification process for organic electronics material | RESONAC CORPORATION (JP) | 2007-07-12 | — | — | US | disclosed |
| US-20060247474-A1 | Method for purifying electroluminescent material, electroluminescent material and electroluminescent device | HITACHI CHEMICAL CO., LTD. (JP) | 2006-11-02 | — | — | US | disclosed |
| US-20020172652-A1 | Composition for film formation and material for insulating film formation | JSR CORPORATION (JP) | 2002-11-21 | — | — | US | disclosed |
| EP-0745073-B1 | 5-SUBSTITUTED DERIVATIVES OF MYCOPHENOLIC ACID | SYNTEX INC (US) | 2000-07-12 | — | — | EP | disclosed |
| EP-0745072-B1 | 4-AMINO DERIVATIVES OF 5-SUBSTITUTED MYCOPHENOLIC ACID | SYNTEX INC (US) | 1998-05-06 | — | — | EP | disclosed |
| US-5633279-A | 5-substituted derivatives of mycophenolic acid | SYNTEX (U.S.A.) INC. (US) | 1997-05-27 | — | — | US | disclosed |
| US-5538969-A | IMMUNOSUPPRESSANTS | SYNTEX (U.S.A.) INC. (US) | 1996-07-23 | — | — | US | disclosed |
| US-5536747-A | ENZYME INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1996-07-16 | — | — | US | disclosed |
| US-5525602-A | TREATING INFLAMMATORY DISEASES, PREVENTING ALLOGRAFT REJECTION, AUTOIMMUNE DISEASES | SYNTEX (U.S.A.) INC. (US) | 1996-06-11 | — | — | US | disclosed |
| US-5493030-A | CHEMICAL INTERMEDIATES | SYNTEX (U.S.A.) INC. (US) | 1996-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180327428-A1 | PROCESS OF MAKING CENICRIVIROC AND RELATED ANALOGS | CCR5, CCR2, CCR3 | TSHR 3282/4885ACHE 4678/4885ALDH1A1 4349/4885 |
| US-20200216476-A1 | PROCESS OF MAKING CENICRIVIROC AND RELATED ANALOGS | CCR5, CCR2, CCR3 | TSHR 3282/4885ACHE 4678/4885ALDH1A1 4349/4885 |
| US-20020172652-A1 | Composition for film formation and material for insulating film formation | VCL, BMI1, PUF60 | TSHR 4810/4885ACHE 2387/4885ALDH1A1 2731/4885 |
| US-20060247474-A1 | Method for purifying electroluminescent material, electroluminescent material and electroluminescent device | ITPA, ENTPD2, ALPL | TSHR 4253/4885ACHE 332/4885ALDH1A1 2587/4885 |
| US-20170362207-A1 | PURIFIED CENICRIVIROC AND PURIFIED INTERMEDIATES FOR MAKING CENICRIVIROC | CCR5, CCR2, CXCR3 | TSHR 4134/4885ACHE 4652/4885ALDH1A1 3884/4885 |
| US-20210171504-A1 | Purified cenicriviroc and purified intermediates for making cenicriviroc | CCR5, CCR2, CXCR3 | TSHR 4134/4885ACHE 4652/4885ALDH1A1 3884/4885 |
| US-10407411-B2 | Purified cenicriviroc and purified intermediates for making cenicriviroc | CCR5, CCR2, CXCR3 | TSHR 4134/4885ACHE 4652/4885ALDH1A1 3884/4885 |
| US-20200095229-A1 | Purified cenicriviroc and purified intermediates for making cenicriviroc | CCR5, CCR2, CXCR3 | TSHR 4134/4885ACHE 4652/4885ALDH1A1 3884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.